- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Traws Pharma Inc (TRAW)
The Traws Pharma share price today is 1.430, view NASDAQ TRAW stock exchange data. Track the latest Traws Pharma share price with real-time updates on TRAW stock performance including market cap, day range, 52-week range and dividend yield. Access TRAW charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.270
1.450
52 wk Range
0.970
3.265
TRAW is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2701.450
52 wk Range
0.9703.265
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TRAW Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
5.500
Upside
+284.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.500
(+284.62% Upside)
Traws Pharma Inc Earnings Call Summary for Q4/2025
- Revenue surged 1,100% YoY to $2.8M; net income of $9.2M vs. $166.5M loss in 2024, driven by strategic pivot from oncology to virology.
- Cash position declined to $3.8M from $21.3M; secured private placement financing up to $60M, extending runway through Q1 2027.
- Tivoxavir marboxil Phase IIa trials targeted for mid-2025; company projects $4.9M revenue by 2026 despite anticipated EPS losses through 2026.
- Stock trades at $1.13, down 29% from $1.59 close, near 52-week low of $0.97; analysts maintain bullish outlook with $3-$8 price targets.
- FDA clinical hold on Tivoxavir remains key risk; management confident in addressing regulatory concerns to advance influenza prophylactic program.
Last Updated: 16-04-2026, 10:30 pm
Read Full TranscriptEarnings
Latest Release
15-04-2026
EPS / Forecast
-0.57 / -9.56
Revenue / Forecast
-- / --
Compare TRAW to Peers and Sector
Metrics to compare | TRAW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRAWPeersSector | |
|---|---|---|---|---|
P/E Ratio | 2.1x | −1.7x | −0.5x | |
PEG Ratio | 0.02 | −0.02 | 0.00 | |
Price/Book | −23.1x | 1.5x | 2.6x | |
Price / LTM Sales | 5.2x | 4.5x | 3.2x | |
Upside (Analyst Target) | 323.1% | 50.2% | 50.8% | |
Fair Value Upside | Unlock | 13.0% | 7.7% | Unlock |
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Traws Pharma (TRAW) Share Price Today?
The Traws Pharma share price today is 1.430.
What is the current Traws Pharma (TRAW) share price and day range?
As of 01-05-2026, the Traws Pharma share price is 1.430, with a previous close of 1.300. The share price has ranged from 1.270 to 1.450 today, while the 52-week range spans from 0.970 to 3.265.
What Is the Traws Pharma Market Cap?
As of today, Traws Pharma market cap is 14.370M.
What Is the Traws Pharma (TRAW) Share Price Target?
The average 12-month share price target for Traws Pharma is 5.500, with a high estimate of 8 and a low estimate of 3. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +284.62% Upside potential.
What Is Traws Pharma's Earnings Per Share (TTM)?
The Traws Pharma EPS (TTM) is 0.834.
From a Technical Analysis Perspective, Is TRAW a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Traws Pharma Trade On?
Traws Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Traws Pharma?
The stock symbol for Traws Pharma is "TRAW."
How Many Times Has Traws Pharma Stock Split?
Traws Pharma has split 4 times.
How Many Employees Does Traws Pharma Have?
Traws Pharma has 6 employees.
What Is the TRAW Premarket Price?
TRAW's last pre-market stock price is 1.330. The pre-market share volume is 12,370.000, and the stock has changed by 0.030, or 2.310%.
What Is the TRAW After Hours Price?
TRAW's last after hours stock price is 1.421, the stock has changed by -0.009, or -0.610%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.